Silent Ischemia Found on Pre-Operative Testing: Medical Therapy Alone or Further Workup?
She has never had a symptom in twelve years of diabetes, and the ischemia on her stress test was found only because her knee surgery required testing that wasn't looking for it.
S.N., a 55-year-old woman, has spent the last twelve years treating her type 2 diabetes the way she treats her clients' books — carefully, on a schedule, with regular checkups she doesn't skip. Her A1c has held around 7% for the better part of three years, she walks most mornings before work, and she has never, in her own words, had a day where her chest bothered her. The abnormal finding that brought her to cardiology wasn't a symptom at all; it turned up on a routine exercise stress test ordered as pre-operative clearance for a knee replacement she's had scheduled for months, in the middle of her firm's busiest season.
The test showed reversible inferior wall ischemia at a moderate workload — a finding that, in someone with chest pain, would be a straightforward case for further workup. In her, there is no symptom to correlate it with, and no way to know from the test alone whether it represents a lesion that would benefit from revascularization or a degree of diabetic coronary disease better served by not looking for trouble that isn't currently causing any. The DIAD trial asked close to this exact question in a cohort of asymptomatic diabetics screened for silent ischemia, and its finding — that randomizing asymptomatic diabetics to stress-imaging screening rather than to no screening at all didn't reduce cardiac events over nearly five years, with both arms receiving active medical management throughout — is the most directly relevant evidence the team has for what to do with a woman who, by her own account, feels entirely well.
In clinic, before pre-operative clearance
She's exactly the population DIAD enrolled — asymptomatic, diabetic, found to have silent ischemia on screening — and that trial's result was clear: randomizing to screening rather than to no screening didn't lower cardiac events, with both arms managed medically throughout. I don't think an incidental finding in a woman with no symptoms and reasonably controlled diabetes should trigger a cardiac catheterization she wouldn't otherwise have needed.
If she had any exertional symptoms at all, even mild ones she'd dismissed as unrelated, I'd read this completely differently — a positive stress test with a plausible symptom to match it is a different clinical situation than the same finding in someone who is genuinely asymptomatic.
I agree DIAD argues against routine screening and reflexive revascularization for silent ischemia, but I want to be careful about over-applying a population-level trial result to her specific test. Reversible ischemia at a moderate workload isn't a trivial finding, and we don't actually know the extent or location of disease without further imaging. I'm not proposing catheterization tomorrow, but I do think a coronary CT angiogram, which is noninvasive, is reasonable before we commit fully to a medical-therapy-alone plan and clear her for a knee replacement that itself carries perioperative cardiac stress.
I take the DIAD point seriously, but that trial's medical-management arm still involved careful escalation of secondary-prevention therapy, not doing nothing — the finding supports intensifying her medical regimen aggressively, which we haven't done yet, not concluding that the anatomy underneath the finding is irrelevant to her perioperative risk.
The most defensible read of DIAD is that it supports intensifying secondary prevention rather than pursuing invasive workup by default — her statin isn't at high intensity yet, and she isn't on aspirin or a beta-blocker despite a positive ischemia finding. I'd move her to high-intensity statin therapy and add aspirin and a low-dose beta-blocker — but I want to be exact about why the beta-blocker is going on, because the reasoning matters more than the drug. It is for the ischemia finding itself, started now and titrated slowly over weeks, and it is emphatically not perioperative prophylaxis. POISE settled that question the other way: beta-blockade begun shortly before noncardiac surgery in a previously beta-blocker-naive patient did cut nonfatal MI, but at the cost of more stroke and higher all-cause mortality, largely through hypotension and bradycardia, and starting one on the day of surgery is now a recommendation against harm rather than a recommendation for benefit. Her knee replacement is already on hold, which gives us the weeks we need to do this properly — if it weren't, I would be arguing to leave her beta-blocker-naive through the operation. The same timing logic applies to the aspirin: it goes on for her ischemia, not as a perioperative measure, since starting aspirin around surgery has been tested and produced bleeding rather than protection. A coronary CTA is a reasonable middle step if there's genuine uncertainty about extent of disease, but it shouldn't be positioned as a gateway to revascularization she doesn't yet have evidence she needs.
Agreed: statin intensified to high dose, aspirin and low-dose metoprolol started now for the ischemia finding rather than as perioperative prophylaxis, with enough runway to titrate before surgery, and a coronary CT angiogram ordered to clarify disease extent.
Not agreed, and the actual branch point sits with what that CTA shows:
Her knee replacement proceeds on intensified medical therapy alone, with no further invasive workup planned.
The revascularization conversation reopens on different grounds — anatomy, not the original silent-ischemia finding alone.
Her surgery stays on hold until the CTA result is back, regardless of which branch it points toward.